Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-02
1997-06-03
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, A61K 3600, C07K 1400
Patent
active
056354797
ABSTRACT:
A process for treating a gynecological malignancy in a host which comprises administering to the host at least one biologically active amphiphilic peptide or protein. The peptide or protein may be administered intralesionally, intravenously, or intraperitoneally, whereby the peptide or protein may inhibit, prevent, or destroy the growth of the gynecological malignancy, such as an ovarian cancer, uterine cancer, or cervical cancer.
REFERENCES:
patent: 4810777 (1989-03-01), Zasloff
patent: 4962277 (1990-10-01), Cuervo et al.
patent: 5073542 (1991-12-01), Zasloff
Ozols et al., Kinetic Characterization and Response to Chemotherapy in a Transplantable Murine Ovarian Cancer, Cancer Research, vol. 39, No. 8, CNREAB 8, pp. 2909-3288 (1979).
Cecil's Textbook of Medicine, ed. Wyngaarden, Smith, Jr. and Bennett, pp. 1395-1397 (19th Edition).
Baker et al., "Anticancer Efficacy of Magainin2 and Analogue Peptides," Cancer Research, vol. 53, pp. 3052-43057, (Jul. 1, 1993).
Baker Margaret A.
Jacob Leonard S.
Maloy W. Lee
Magainin Pharmaceuticals Inc.
Schain Howard E.
Touzeau P. L.
LandOfFree
Treatment of gynecological malignancies with biologically active does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of gynecological malignancies with biologically active, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of gynecological malignancies with biologically active will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-391674